4.7 Article

Impact of treatment duration on recurrence of chronic pulmonary aspergillosis

期刊

JOURNAL OF INFECTION
卷 83, 期 4, 页码 490-495

出版社

W B SAUNDERS CO LTD
DOI: 10.1016/j.jinf.2021.07.030

关键词

Chronic pulmonary aspergillosis; Duration of therapy; Recurrence; Comparative study

资金

  1. Samsung Medical Center Grant [OTA2002901]

向作者/读者索取更多资源

For patients with chronic pulmonary aspergillosis (CPA), extending antifungal therapy beyond 12 months can significantly reduce the recurrence rate.
Objectives: Limited data exist on the optimal treatment duration for chronic pulmonary aspergillosis (CPA). We investigated the treatment outcome and recurrence rate according to treatment duration in CPA patients. Methods: A total of 196 patients who completed at least 6 months of antifungal therapy (99% oral itraconazole) and achieved favorable treatment responses were analyzed. A Cox's proportional hazards regression model was used to adjust for potential confounding factors in the association between the duration of antifungal therapy (6-12 months vs. >= 12 months) and recurrence. Results: All patients were treated with antifungal agents for at least 6 months (median: 12.5, interquartile range: 8.5-18.4 months) and categorized into 6-12 months group (79/196, 40%) and >= 12 months group (117/196, 60%). The 6-12 months group had significantly higher recurrence rates owing to CPA aggravation after the completion of treatment compared with the >= 12 months group (51% vs. 25%, P = 0.003). In a Cox's proportional hazards regression model, treatment duration >= 12 months was independently associated with a lower risk of recurrence (adjusted hazard ratio: 0.48, 95% confidence interval: 0.28-0.80). Conclusions: Our data suggest that prolonging antifungal therapy beyond 12 months could reduce the recurrence rate in CPA patients. (C) 2021 Published by Elsevier Ltd on behalf of The British Infection Association.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据